Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PLx Pharma wins grant to conduct Patent ductus arteriosus research
The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PLx Pharma and UTHealth are working to reduce the GI toxicity of
The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PLx Pharma and UTHealth are working to reduce the GI toxicity of
The trial was designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide. The study met its primary end-point,
The collaboration aims to expand the footprint of Intelsius and its core strategy of offering products globally with local supply. Intelsius CEO David Walsh said the company’s partnership
Omontys injection is a synthetic, pegylated, peptide-based erythropoiesis stimulating agent (ESA). Nektar provides its partner Affymax with its proprietary PEGylation technology for use in Omontys. Two Phase 3
The goal of Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the
The study, which is being conducted at multiple sites across Southern Ontario, will evaluate the safety and pharmacokinetics of single ascending doses of TTI-1612 in IC/BPS patients. TTI-1612
The study reported that significantly more patients achieved at least a 75% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo
The launch of bioequivalent generic version of SEROQUEL tablets is followed by the FDA approval of Dr Reddy’s ANDA. Quetiapine fumarate tablets in 25mg and 50mg are available
As per the agreement, NGM will apply its integrated discovery technology and in vivo screening platform to identify and validate physiologically-relevant metabolic targets that modulate beta-cell growth and
The milestone payment is related to the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial. The HuCAL-derived, fully human antibody will be developed